Neil Chatterji
Stock Analyst at B. Riley Securities
(1.70)
# 3,381
Out of 5,090 analysts
19
Total ratings
29.41%
Success rate
4.39%
Average return
Main Sectors:
Stocks Rated by Neil Chatterji
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLPT ClearPoint Neuro | Maintains: Buy | $20 → $28 | $13.54 | +106.79% | 4 | Apr 25, 2025 | |
| OPRX OptimizeRx | Maintains: Buy | $17 → $13 | $14.24 | -8.71% | 3 | Dec 24, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $95 → $50 | $70.79 | -29.37% | 2 | Nov 9, 2023 | |
| ARAY Accuray | Reiterates: Buy | $7.5 | $0.99 | +661.04% | 1 | Oct 4, 2023 | |
| ZUMZ Zumiez | Maintains: Neutral | $15 → $18 | $30.62 | -41.21% | 2 | Sep 8, 2023 | |
| KRMD KORU Medical Systems | Initiates: Buy | $4.5 | $5.57 | -19.21% | 1 | Sep 7, 2023 | |
| HYPR Hyperfine | Maintains: Buy | $2.5 → $3.5 | $1.08 | +224.07% | 3 | Aug 15, 2023 | |
| STXS Stereotaxis | Maintains: Buy | $6 → $5.5 | $2.41 | +128.22% | 2 | Mar 6, 2023 | |
| BFLY Butterfly Network | Initiates: Buy | $9.5 | $3.06 | +210.46% | 1 | Oct 4, 2022 |
ClearPoint Neuro
Apr 25, 2025
Maintains: Buy
Price Target: $20 → $28
Current: $13.54
Upside: +106.79%
OptimizeRx
Dec 24, 2024
Maintains: Buy
Price Target: $17 → $13
Current: $14.24
Upside: -8.71%
Establishment Labs Holdings
Nov 9, 2023
Maintains: Buy
Price Target: $95 → $50
Current: $70.79
Upside: -29.37%
Accuray
Oct 4, 2023
Reiterates: Buy
Price Target: $7.5
Current: $0.99
Upside: +661.04%
Zumiez
Sep 8, 2023
Maintains: Neutral
Price Target: $15 → $18
Current: $30.62
Upside: -41.21%
KORU Medical Systems
Sep 7, 2023
Initiates: Buy
Price Target: $4.5
Current: $5.57
Upside: -19.21%
Hyperfine
Aug 15, 2023
Maintains: Buy
Price Target: $2.5 → $3.5
Current: $1.08
Upside: +224.07%
Stereotaxis
Mar 6, 2023
Maintains: Buy
Price Target: $6 → $5.5
Current: $2.41
Upside: +128.22%
Butterfly Network
Oct 4, 2022
Initiates: Buy
Price Target: $9.5
Current: $3.06
Upside: +210.46%